<DOC>
	<DOCNO>NCT00387972</DOCNO>
	<brief_summary>GW823093 selective DPP-IV Inhibitor investigate day oral therapy . The purpose Study evaluate effectiveness , safety , tolerability 2 dos GW823093 , compare placebo , take daily patient Type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus treat diet exercise oral antidiabetic treatment Body mass index 20 40 Females childbearing potential must use adequate birth control . Exclusion criterion : Subjects previous use insulin Type 1 diabetes Uncontrolled thyroid disease History drug alcohol abuse past year Any clinically significant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Type 2 diabetes mellitus ( T2DM )</keyword>
	<keyword>glycosylated hemoglobin ( HbA1c )</keyword>
	<keyword>denagliptin</keyword>
	<keyword>diabetes treatment</keyword>
	<keyword>glycemic control</keyword>
</DOC>